P2Rx6 Protein — Purinergic Receptor P2X Subunit 6 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
P2RX6 encodes the P2X receptor subunit 6, an ATP-gated cation channel that plays important roles in purinergic signaling throughout the body. P2X6 is unique among P2X receptor subunits as it has been shown to require assembly with other subunits (particularly P2X4) to form functional heteromeric channels. The receptor is expressed in various tissues including the brain, spinal cord, and immune cells, where it participates in ATP-mediated signaling cascades relevant to neurodegeneration and neuroinflammation [Citation 1].
The P2X receptor family consists of seven subunits (P2X1-P2X7) that form ligand-gated ion channels upon ATP binding. While P2X6 has been less studied than other family members, emerging research suggests important roles in synaptic transmission, microglial activation, and inflammatory responses in the brain [Citation 2].
| Field | Value |
|-------|-------|
| **Protein Name** | P2RX6 / P2X6 |
| **Gene Symbol** | P2RX6 |
| **Chromosome** | 22q11.21 |
| **Gene ID** | [5305](https://www.ncbi.nlm.nih.gov/gene/5305) |
| **UniProt ID** | [Q9R9E9](https://www.uniprot.org/uniprot/Q9R9E9) |
| **Molecular Weight** | ~42 kDa |
| **Amino Acids** | 379 |
| **Subcellular Localization** | Plasma membrane, Endoplasmic reticulum |
| **Protein Family** | P2X receptor family (ATP-gated ion channels) |
| **Structure** | Trimeric ATP-gated ion channel |
| **Brain Expression** | Cortex, Hippocampus, Spinal cord, Microglia |
P2X6 subunits share the common structural features of P2X receptors:
| Feature |
Description |
| N-terminus |
Intracellular, ~25 amino acids |
| TF domain 1 |
Transmembrane helix |
| **Extracellular loop |
ATP-binding domain (~280 residues) |
| TF domain 2 |
Second transmembrane helix |
| C-terminus |
Intracellular, ~30 amino acids |
P2X6 has several distinctive characteristics:
- O-glycosylation sites: Unique among P2X subunits
- Cysteine-rich extracellular loop: Differs from other P2X receptors
- ER retention: P2X6 subunits are often retained in ER when unassembled
- Hetero-oligomerization requirement: Functional channels typically require P2X4 co-assembly [Citation 3]
The P2X6 subunit preferentially forms heteromeric channels with P2X4:
- P2X4/6 composition: Typically 2 P2X4 + 1 P2X6 subunits
- Pharmacological profile: Distinct from homomeric P2X4 or P2X6
- Physiological significance: May be the predominant functional form in vivo
ATP acts as an extracellular signaling molecule through P2X receptors:
Signaling Cascade:
- ATP is released from neurons, astrocytes, or damaged cells
- ATP binds to P2X6 (usually as P2X4/6 heteromer)
- Channel opens, allowing Na+ and Ca2+ influx
- Intracellular signaling cascades are activated
- ATP is hydrolyzed by ectonucleotidases to terminate signaling
In the central nervous system, P2X6 receptors participate in:
Synaptic Transmission:
- Modulation of neurotransmitter release
- Postsynaptic depolarization
- Calcium signaling in dendritic spines
Glial Function:
- Microglial activation and migration
- Astrocyte calcium waves
- Neuroimmune communication [Citation 4]
Pain Signaling:
- Spinal cord pain processing
- Nociceptive neuron activation
P2X6 is expressed in:
- Brain: Cortex, hippocampus, cerebellum, thalamus
- Spinal cord: Dorsal horn (pain pathways)
- Peripheral nervous system: Sensory neurons
- Immune cells: Macrophages, lymphocytes
- Other organs: Lung, testis, spleen [Citation 5]
Alzheimer's Disease:
- Altered P2X6 expression in AD brain
- May contribute to Aβ-induced inflammation
- Microglial P2X4/6 channels modulate neuroinflammation
Parkinson's Disease:
- P2X receptor changes in substantia nigra
- May affect dopaminergic neuron survival
- ATP signaling in glial cells
Amyotrophic Lateral Sclerosis (ALS):
- Dysregulated purinergic signaling in ALS
- Altered microglial P2X responses
- Potential therapeutic target [Citation 6]
P2X6 in pain pathways:
- Spinal cord dorsal horn signaling
- Neuropathic pain development
- Inflammatory pain modulation
- Autoimmune disorders
- Inflammatory bowel disease
- Rheumatoid arthritis
P2X6 and P2X4/6 channels represent therapeutic targets:
Drug Development Challenges:
- Limited selective antagonists for P2X6
- Heteromeric channel complexity
- BBB penetration requirements
Potential Therapeutic Approaches:
- P2X4/6 antagonists: Selective inhibition of heteromeric channels
- Allosteric modulators: Targeting subunit interfaces
- Gene therapy: Modulating P2X6 expression
| Receptor |
Channel Type |
Agonist |
Antagonist |
Therapeutic Focus |
| P2X4 |
Homomeric |
ATP |
BBG |
Pain, MS |
| P2X6 |
Heteromeric |
ATP |
None |
Inflammation |
| P2X7 |
Homomeric |
BzATP |
A-438079 |
Cancer, Inflammation |
| Partner |
Interaction Type |
Function |
| P2X4 |
Heteromer formation |
Functional channel |
| P2X1 |
Possible heteromer |
Channel assembly |
| ATP |
Ligand |
Channel activation |
| A-438079 |
Antagonist |
Inhibition |
| NF-κB |
Downstream |
Transcription regulation |
| ERK1/2 |
Downstream |
Signaling cascade |
- Structure and function of P2X6 receptors. J Neurosci, 2000.
- P2X receptor family in neurodegeneration. Nat Rev Neurosci, 2004.
- P2X4/6 heteromeric channels. J Biol Chem, 2005.
- Purinergic signaling in glia. Glia, 2009.
- P2X receptors in CNS function. Brain Res Rev, 2011.
- P2X6 in neuroinflammation. J Neuroinflammation, 2015.
Page updated: 2026-03-07
The study of P2Rx6 Protein — Purinergic Receptor P2X Subunit 6 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neurodegenerative Disease Research - Comprehensive reviews on disease mechanisms
- Alzheimer's Association - Disease information and current research
- NIH National Institute on Aging - Research updates and clinical trials